InvestorsHub Logo
Followers 41
Posts 6356
Boards Moderated 1
Alias Born 04/10/2012

Re: NASDAQ2020 post# 98372

Wednesday, 03/19/2014 12:07:04 AM

Wednesday, March 19, 2014 12:07:04 AM

Post# of 407746
You know, I’ve thought about the filing today. I've thought about it a lot. And I have come to several conclusions:

A - Nasrat and company (board of directors) are HUGE owners of ELTP stock. Any increase in authorized/outstanding shares will hit them as well as us.

*Also, if a reverse split is on the table later down the road, they (Nasrat and company) will be converted along with all other shareholders. Nasrat has acknowledged this and is clearly confident that Elite would succeed even with a R/S performed. He has clearly stated this would be done from a position of strength, if at all.*

B - Since Nasrat has come aboard with Elite, we have made tremendous progress with our ART technology, securing multiple successful trial results after a long hiatus. We also have trials pending and more to be initiated. We have a slew of generic drugs in the queue and on the verge of launching. We have a third patent that has been approved on our ART technology.

C - Last but not least. I am specifically reminded of a time in 2011 when Elite wanted to increase the A/S from 355,517,588 shares (334,482,412 increase) to a total of 690,000,000 shares authorized.

Link - http://www.elitepharma.com/ELTP%20FY2011%20DEF14A.pdf

I was apprehensive at that time, but I stuck with my company and I stuck with my investment. I did and still do believe in the technology this company possesses. 3 years later, I am now up over 4x my total investment in Elite Pharmaceuticals as of today (and was up about 8x in the .90s). My point here is that even though the company has nearly doubled the share count in the past, they have still managed to increase the value of the shares many times over (from 2011 lows). Obviously, while dilution is not a preferred method of funding by investors, the company has proven that it can still generate value in spite of this. I am confident that with Nasrat at the helm of Elite Pharmaceuticals, our investments in this company will continue to flourish.

Cheers longs. Our best days lie ahead, in my opinion.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News